Article
G&L to join esteemed panel at Biocom California event
Posted on the 26th September 2024
G&L Healthcare Advisors is proud to announce its participation at Biocom California’s upcoming event, Maximize Your Drug Asset Value & Commercial Success.
The panel discussion will take place on October 2nd, 2024, at Biocom California's offices in San Diego, bringing together biopharma professionals and industry leaders to share insights on asset differentiation and strategies for improving commercial viability throughout the drug development lifecycle.
Representing G&L on the panel will be Dr. Steven Hildemann, MD, PhD, R&D Physician at G&L.
He will be joined by industry experts including Krishna Allamneni, Executive Vice President, Chief Development Officer at Concarlo Therapeutics, Inc., Jamie Sulley, SVP Global Regulatory Affairs at Secura Bio Inc., Lesley Stolz, Vice President, Early Innovation Partnering at Johnson & Johnson Innovation, and Dr. Michael J. Nowak, Managing Partner, Nowak Ventures, LLC.
Together they will explore how biopharma companies can leverage regulatory, clinical, and commercial insights to overcome development challenges and increase asset value at key stages.
Their diverse perspectives, from regulatory affairs to clinical expertise and strategic consulting, provide a comprehensive view of how to navigate the complexities of drug development.
Speaking about the event, Dr. Hildemann said:
“G&L Healthcare Advisors is thrilled to be part of this important conversation.
“This is an excellent opportunity to engage with our peers and share our expertise on regulatory engagement and clinical and commercial development strategies.
“At G&L, we are committed to helping companies navigate the complex regulatory landscape and develop effective strategies that ensure both clinical and commercial success.”
Key topics
This panel is essential for professionals across the biopharma industry, including those in regulatory affairs, clinical development, and C-suite leadership, who are seeking insights to enhance their commercial strategies and optimize their drug development pipeline.
Areas that will be discussed include best practices for early regulatory engagement and strategies for Phase III success, navigating commercial challenges in drug development and increasing asset differentiation, and leveraging competitive intelligence and global market access.
G&L is ready to provide personalized solutions that align with your specific objectives across every aspect of regulatory affairs, quality assurance, advisory services, market access, and drug development strategy.
Find out more at: www.gandlhealth.com